Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 14Other solid neoplasm 13Tumor-Agnostic 11Genitourinary 11Gastrointestinal 11Breast 10Lymphoid 7Dermatologic 6Sarcoma 5Other hematologic neoplasm 5CNS 4Head & Neck 2Plasma cell 1Other 1Gynecologic 1Endocrine 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1

Interventions

Dexamethasone 870Lenalidomide 456Bortezomib 454Cyclophosphamide 365Melphalan 271Calcium Dobesilate 262daratumumab 233pomalidomide 207carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74Cyclosporine 68isatuximab 67auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 56Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Midazolam × Plasma cell × Clear all
NCT01456689 2020-12-17

A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

Novartis

Phase 1 Completed
79 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡